Universidade de São Paulo, Faculdade de Medicina, São Paulo, SP, Brasil.
Clínica Gastrosaude, Marilia, SP, Brasil.
Arq Gastroenterol. 2020 Oct-Dec;57(4):507-510. doi: 10.1590/S0004-2803.202000000-76.
Therapeutic drug monitoring (TDM) of infliximab (IFX) has been recognized as an important strategy in the management of secondary loss of response to this agent, guiding clinical decision-making in the management of inflammatory bowel diseases (IBD). Although most of the data on the application of TDM for IFX refer to the maintenance phase of treatment, many studies have associated higher drug concentrations, specially in the induction phase, with achievement of important treatment targets, such as clinical remission and mucosal healing. This brief communication aims to summarize the literature on the use of TDM during induction phase of IFX and propose application of a simplified approach which can be useful into clinical practice, aiming better outcomes to IBD patients.
英夫利昔单抗（IFX）的治疗药物监测（TDM）已被认为是管理该药物继发应答丧失的重要策略，指导炎症性肠病（IBD）管理中的临床决策。尽管大多数关于 IFX TDM 应用的数据都涉及治疗的维持阶段，但许多研究表明，药物浓度较高，特别是在诱导阶段，与实现重要的治疗目标（如临床缓解和黏膜愈合）相关。本简要通讯旨在总结 IFX 诱导期 TDM 使用的文献，并提出一种简化方法的应用，该方法可能对临床实践有用，旨在改善 IBD 患者的预后。
